FY2030 Earnings Estimate for MediWound Issued By Maxim Group

MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at Maxim Group lowered their FY2030 earnings estimates for shares of MediWound in a research report issued to clients and investors on Monday, March 9th. Maxim Group analyst M. Okunewitch now anticipates that the biopharmaceutical company will post earnings of $2.99 per share for the year, down from their prior forecast of $3.06. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share.

MDWD has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, MediWound has a consensus rating of “Hold” and an average price target of $31.67.

MediWound Price Performance

Shares of NASDAQ:MDWD opened at $16.58 on Thursday. The company has a market cap of $212.39 million, a P/E ratio of -7.90 and a beta of 0.13. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The stock’s fifty day moving average price is $17.60 and its 200-day moving average price is $17.86.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.09. The business had revenue of $1.87 million for the quarter, compared to the consensus estimate of $2.09 million. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.

Institutional Investors Weigh In On MediWound

A number of large investors have recently made changes to their positions in MDWD. Quarry LP bought a new position in shares of MediWound in the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets boosted its holdings in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the last quarter. Russell Investments Group Ltd. grew its position in MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in MediWound during the fourth quarter valued at approximately $109,000. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.